Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Pulmonary Neuroendocrine Neoplasm|Pheochromocytoma|Paraganglioma|Thymus Carcinoid|Unknown Primary Tumors|Neuroendocrine Tumors|Neuroendocrine Skin Carcinoma|Neuroendocrine Breast Tumor|Neuroendocrine Carcinoma Metastatic|Neuroendocrine Neoplasm of Ovary
Interventions: DRUG: 177Lu-DOTATOC
Sponsor: Excel Diagnostics and Nuclear Oncology Center